Literature DB >> 9285216

Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum-toxin therapy: long-term results.

P Roggenkämper1, Z Nüssgens.   

Abstract

Thirty-one patients with essential blepharospasm or lid opening disorder of the levator-inhibiting type, unresponsive to treatment with botulinum toxin, underwent frontalis suspension. Twenty-eight patients received bilateral surgery (three patients with bilateral complaints of different severity were operated on the more affected side; these patients were not included in the statistical analysis). The mean age was 62.4 years +/- 8.52 (range 42-80 years). The individual improvement of complaints was assessed by the patients using a percentage scale (0% = no improvement; 100% = no complaints). Objective and subjective improvement was achieved in 26 of 28 patients. The mean subjective improvement was 57.7% +/- 31.4. In 23 cases an additional treatment with botulinum toxin was administered. During follow-up period (mean 22.1 months +/- 11.6; range 5-40 months) the effect of surgery remained stable. There were no serious complications, in a 5 of 56 operated eyes suture granuloma had developed. Unlike other surgeries for treatment of blepharospasm (excision of the orbicularis muscle, resection of facial nerve branches) frontalis suspension can be considered as a minimally invasive, but very effective and (if desired) reversible procedure. Moreover, additional treatment with botulinum toxin can bring about further improvement.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285216     DOI: 10.1007/bf00947004

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

1.  APRAXIA OF LID OPENING.

Authors:  J E GOLDSTEIN; D G COGAN
Journal:  Arch Ophthalmol       Date:  1965-02

Review 2.  So-called apraxias of lid movement.

Authors:  F E Lepore
Journal:  Adv Neurol       Date:  1988

3.  Adjustable eyelid and eyebrow suspension for blepharoptosis.

Authors:  M R Carlson; A Jampolsky
Journal:  Am J Ophthalmol       Date:  1979-07       Impact factor: 5.258

4.  Apraxia of lid opening.

Authors:  J Jankovic
Journal:  Mov Disord       Date:  1995-09       Impact factor: 10.338

5.  Frontalis suspension for essential blepharospasm unresponsive to botulinum toxin therapy. First results.

Authors:  P Roggenkämper; Z Nüssgens
Journal:  Ger J Ophthalmol       Date:  1993-11

6.  Long-term treatment of blepharospasm with botulinum toxin type A.

Authors:  Z Nüssgens; P Roggenkämper
Journal:  Ger J Ophthalmol       Date:  1995-11

7.  Treatment of blepharospasm with botulinum toxin. A preliminary report.

Authors:  B R Frueh; D P Felt; T H Wojno; D C Musch
Journal:  Arch Ophthalmol       Date:  1984-10

8.  Botulinum A toxin injection as a treatment for blepharospasm.

Authors:  A B Scott; R A Kennedy; H A Stubbs
Journal:  Arch Ophthalmol       Date:  1985-03

9.  [Blepharospasm treatment with botulinum toxin (follow-up)].

Authors:  P Roggenkämper
Journal:  Klin Monbl Augenheilkd       Date:  1986-10       Impact factor: 0.700

  9 in total
  4 in total

1.  [What to do in cases of inadequate effectiveness of botulinum toxin for the treatment of eyelid cramping?].

Authors:  P Roggenkämper
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

2.  Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07-28       Impact factor: 3.117

3.  Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results.

Authors:  Dirk Dressler; Chrisanthi Karapantzou; Saskia Rohrbach; Simon Schneider; Rainer Laskawi
Journal:  J Neural Transm (Vienna)       Date:  2016-11-05       Impact factor: 3.575

4.  Frontalis suspension surgery to treat patients with essential blepharospasm and apraxia of eyelid opening-technique and results.

Authors:  Chrisanthi Karapantzou; Dirk Dressler; Saskia Rohrbach; Rainer Laskawi
Journal:  Head Face Med       Date:  2014-10-22       Impact factor: 2.151

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.